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Abstract
The goal of the study was to examine secreted protein response and withdrawal profiles from 
cultured human trabecular meshwork (HTM) cells following short- and long-term glucocorticoid 
treatment. Primary cultures of five human HTM cell strains isolated from 5 different individual 
donor eyes were tested. Confluent HTM cells were differentiated in culture media containing 1% 
FBS for at least one week, and then treated with Dexamethasone (Dex, 100 nM) 3 times/week for 
1 or 4 weeks. Cell culture supernatant was collected 3 times per week for 8 weeks. Secretion 
profiles of myocilin (MYOC), matrix metalloproteinase-2 (MMP2) and fibronectin (FN) were 
determined by Western blot analysis and MMP2 activity by zymography. Dex treatment reduced 
MMP2 expression and activity, returning to normal levels shortly after Dex withdrawal in 5 HTM 
cell strains. All five cell strains significantly upregulated MYOC in response to Dex treatment by 
an average of 17-fold, but recovery to basal levels after Dex withdrawal took vastly different 
periods of time depending on cell strain and treatment duration. Dex treatment significantly 
increased FN secretion in all strains but one, which decreased FN secretion in the presence of Dex. 
Interestingly, secretion of FN and MYOC negatively correlated during a 4 week recovery period 
following 4 weeks of Dex treatment. Taken together, the time course and magnitude of response 
and recovery for three different secreted, extracellular matrix-associated proteins varied greatly 
between HTM cell strains, which may underlie susceptibility to glucocorticoid-induced ocular 
hypertension.
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Glucocorticoids (GC) have been a mainstay of therapy in reducing systemic and ocular 
inflammation since the 1950s (Gordon, 1956). However, GC use often induces ocular 
hypertension, optic nerve head damage, and visual field defects if left untreated. Elevation of 
intraocular pressure (IOP) usually occurs weeks to months after GC administration, and 
happens in ~40% of patients without glaucoma, called “steroid responder”, and interestingly 
in up to 90% of open angle glaucoma (OAG) patients (Becker and Mills, 1963; Bernstein et 
al., 1963; Jones and Rhee, 2006; Kersey and Broadway, 2006).
The exact mechanism for the GC-induced IOP elevation is uncertain, but due to its time 
course likely involves at least two cellular processes in the resistance-generation region of 
the conventional outflow pathway: increased barrier function at the inner wall of Schlemm’s 
canal (SC) and alterations in cell contractility and extracellular matrix (ECM) turnover in the 
trabecular meshwork (TM) (Clark and Wordinger, 2009). Morphological examination of the 
TM in patients having GC-induced glaucoma shows increased deposition of extracellular 
materials, specifically, increased ECM content in the juxtacanalicular tissue (cribriform 
region) (Johnson et al., 1997; Overby et al., 2014; Ueda et al., 2002). Moreover, GC 
treatment results in decreased intra-trabecular spaces (Fautsch et al., 2000) as a result of 
increased collagen, fibronectin and elastin deposition and an unbalance in ECM enzymes 
(Theocharis et al., 2016). It has been proposed that reduction in matrix metalloproteinase 
(MMP) activity might lead to enhanced deposition of ECM material in the trabecular 
meshwork and thus induce an elevated juxtacanalicular outflow resistance (Johnson et al., 
1997; Rohen et al., 1973). Furthermore, an imbalance between MMPs and the tissue 
inhibitors of MMPs (TIMPs) within the trabecular meshwork is thought to contribute to 
POAG (Ashworth Briggs et al., 2015). Other common features of GC treated eyes are 
myocilin induction, cytoskeletal rearrangement (Clark et al., 2005; Hoare et al., 2009; Read 
et al., 2007) and inhibition of phagocytosis (Matsumoto and Johnson, 1997), which all may 
contribute to increased outflow resistance. Recently, it was noted that both humans and mice 
on prolonged corticosteroid treatment display increased deposition of basement membrane 
materials below the inner wall of Schlemm’s canal (SC), possibly contributing to increased 
barrier function (Johnson et al., 1997; Overby et al., 2014; Tektas et al., 2010). This was 
modeled in vitro by Alvarado showing that Dex increased junction complexes in both SC 
and TM cells, which resulted in increased transendothelial fluid flow resistance (Underwood 
et al., 1999).
The trabecular meshwork is a porous connective tissue with complex three-dimensional 
structure. The resident TM cells are responsible for maintenance of its unique architecture 
and their ECM constituents. The ECM is a dynamic structure composed of a number of 
different matrix proteins (Acott and Kelley, 2008) that is constantly remodeled by new 
deposition and proteolysis. In the current study, we focused on three secreted ECM-related 
proteins: matrix metalloproteinase-2 (MMP-2); myocillin (MYOC); and fibronectin (FN) 
whose expression is altered by Dex and which have also been shown to play important roles 
in ECM formation and remodeling (Stamer et al., 2013). MMP2, also called type IV 
collagenase is involved in the breakdown of ECM in normal physiological processes. The 
function of MYOC is unknown, however mutations in MYOC is a cause of hereditary open-
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angle glaucoma with ocular hypertension (Gharahkhani et al., 2015; Stone et al., 1997). FN 
is a high-molecular weight ECM glycoprotein whose expression is increased in TM tissues 
and the aqueous humor of glaucoma patients (Acott and Kelley, 2008; Wordinger et al., 
2007).
Cultured human TM cells share many properties with human TM cells in situ (Porter et al., 
2015) (Stamer and Clark, 2016) and are commonly used as a model to study the biological 
effects of corticosteroids (Raghunathan et al., 2015). Our previous study showed that TM 
cells modified the secretion of ECM proteins in response to three different types of GC 
treatment (Stamer et al., 2013). However, the variability in secretory responses by different 
TM cell strains to prolonged GC treatment and after withdrawal is unknown. In the current 
study, we examined primary cultures of HTM cells isolated from five different donor eyes of 
different ages at time of death. Cells were treated with dexamethasone (Dex) for short (1 
week) or long (4 weeks) periods and assessed for individual responses to Dex treatment and 
the temporal expression patterns of the ECM-related proteins after withdrawal.
2. Material and Methods
2.1 HTM cell culture
Five strains of human trabecular meshwork cells (HTM120, 122, 123, 124, and 133) were 
isolated from donors aged 11 months, 54 years, 39 years, 81 years and 79 years, respectively 
at time of death, with no eye disease documented. Cells were isolated and characterized as 
previously described (Stamer et al., 2000; Stamer et al., 1995). Human eye tissues were 
sourced ethically from accredited US eye banks and their research use was in accordance 
with the terms of the informed consents of the donors and/or donor family.
HTM cells in passages 3–6 were seeded into 6 well plates in DMEM containing 10% fetal 
bovine serum (FBS) (Atlanta Biologicals, Atlanta, GA) until the cells reached confluency. 
The cells were then switched to DMEM medium containing 1% FBS for at least 7 days prior 
to experimentation.
2.2 Dexamethasone (Dex) treatment
HTM cells were treated with Dex (100 nM) or vehicle in fresh 1.8 ml DMEM containing 1% 
FBS. The cell culture supernatant was collected 3 times/week and replaced with fresh 
medium containing Dex. After 1 week or 4 weeks of Dex treatment, HTM cells were then 
incubated with fresh media without Dex and the culture media was collected/changed every 
3 days for a total of 8 weeks.
2.3 Western Blot analysis
Media was collected from wells of culture plates 3 times/week for 8 weeks. At end of 8 
weeks, cells were harvested and rinsed twice with cold PBS. Cells were scraped into 0.2 ml 
of lysis buffer (25% glycerol, 0.0625M Tris.HCl, 2% SDS) containing 5% beta 
mercaptoethanol. Cell culture media at each time point was mixed with 4 × loading buffer 
(50% glycerol, 0.125M Tris.HCl, 4% SDS) containing 5% beta mercaptoethanol and boiled 
for 10 min before storing at −20°C. For Western blotting, 24 μl of solubilized proteins 
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containing 4 × loading buffer were loaded into 8% polyacrylamide gel slabs and separated 
via SDS-PAGE. Fractionated proteins were then transferred electrophoretically to 
nitrocellulose membranes. Non-specific binding of antibodies to membranes containing 
transferred proteins was reduced by incubating with Tris-buffered saline with 0.1% Tween 
20 (TBS-T) containing 5% nonfat dry milk (blocking buffer). Monoclonal antibodies against 
MMP2 (1:1000, Calbiochem, Gibbstown, NJ) in blocking buffer were incubated overnight 
with membranes at 4°C. The next day, membranes were washed in TBS-T (3 times for 10 
minutes) and were incubated again in blocking buffer containing horseradish peroxidase-
conjugated secondary antibodies (Jackson ImmunoResearch Laboratories, Inc., West Grove, 
PA) for 1 hour. After incubation, membranes were washed with TBS-T as before. Protein-
antibody complexes were visualized using a chemiluminescent HRP antibody detection 
reagent spray (HyGLO; Denville Scientific, Inc., Metuchen, NJ) and exposure to x-ray film 
(Phenix Research Company, Candler, NC). Antibody complexes were removed from 
membranes using stripping buffer (Thermo Scientific, Rockford, IL), and re-blotted using 
affinity purified polyclonal antibodies raised in rabbits against myocilin (dilution of 300 
ng/ml stock, 1:5000). Detection proceeded as described above. This process was repeated 
using monoclonal antibody recognizing fibronectin (1:1000, Santa Cruz Biotechnology, Inc., 
Santa Cruz, CA) and the same detection process as above. The protein abundance in each 
band was quantified by densitometry using ImageJ image analysis software (GeneSnap/
GeneTools; Syngene, Frederick, MD).
In order to compare the three treatments (con, dex 1w and dex 4w), samples were controlled 
in three ways: 1) the same cell number of cells were seeded into 6-well plates, treated with 
same amount of media with identical volumes of media loaded onto gels to run Western blot 
(loading control). 2) The three samples at each time point were run on the same blot and the 
protein levels were normalized by the total proteins in the membrane using Pierce™ 
Reversible Protein Stain Kit for Nitrocellulose Membranes (Thermal Scientific, Waltham, 
MA) (internal control). 3) At end of the 8 weeks, total cell lysates from each well were 
collected, and identical volumes of each sample were tested using Western blot analysis for 
beta-actin content with monoclonal antibodies (1:5000, Sigma, St. Louis, MO) to verify that 
the same number of the cells were present in each well (Cell number control). After the 
normalizations, differences of three protein levels represent the different protein secretion 
profiles following short- and long-term Dex treatment.
2.4 Assessment of gelatinase activity by zymography
Zymography was performed as described previously (Frankowski et al., 2012). Briefly, 
conditioned media from HTM cells was mixed with 4× Laemmli buffer (50% glycerol, 
0.125M Tris.HCl, 4% SDS) and incubated for 10 minutes at room temperature. Samples 
were loaded (10 μl/well) into substrate incorporated polyacrylamide gels (10 % v:v Tris–
HCl acrylamide gels containing 0.1 % (w/v) gelatin, BioRad, Hercules, CA.) and proteins 
separated at a constant current of 60mA. Gels were then washed 3 times with washing buffer 
(2.5% Triton X-100 in ddH2O), 15 minutes per wash and then incubated with zymographic 
development buffer (50mM Tris-HCl, pH 7.4; 200mM NaCl; 50mM CaCl2) for 24 hours at 
37°C. Gels were stained with 0.2% Coomassie blue for 2 hours, then de-stained for 1–2 
hours and areas void of blue stain were indicative of areas of enzyme activity. Semi-
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quantitative densitometric analysis was performed on all gels to determine the extent of 
enzymatic digestion using ImageJ software (GeneSnap/GeneTools; Syngene, Frederick, 
MD) and expressed as the intensity of total-MMP2 bands of interest (72 kDa pro-form and 
68 kDa active-form).
2.5 Statistics
Normality assumption of data (MYOC and FN in 4 weeks Dex treatment and recovery 
groups) was tested. Non-parametric correlation tests (Spearman and Kendall Tau) were used 
to measure total and between-group correlation between MYOC and FN in 4 weeks Dex 
treatment and 4 weeks recovery groups. The between-group correlation was obtained by 
averaging the FN and MYOC values for each cell strain across 4 weeks treatment and 4 
weeks recovery time points, and then computing correlation coefficient across the 5 cell 
strains. Mann–Whitney U test was used to analyze statistical significant difference between 
groups. A P value ≤ 0.05 was considered statistically significant.
3. Results
In order to better understand the spectrum of responses to GCs, we monitored the secretion 
of three different ECM-related proteins (MYOC, MMP2 and FN) from five different HTM 
cell strains, exposed to either 1 week or 4 weeks of dexamethasone (100 nM) treatment. We 
then followed the secretion of these three proteins after treatment was stopped, terminating 
the experiments after 8 weeks for a total of 21 time points for each cell strain. Thus, cells 
treated for one week were followed for an additional seven weeks, while cells treated for 4 
weeks were observed for an additional 4 weeks after Dex withdrawal. Shown in figure 1 are 
representative western blot data from these five HTM cell strains at weekly intervals for total 
8 weeks. Treatments did not appear to alter cell morphology over the eight weeks of study 
(supplemental figure 1).
3.1 Myocilin
To better compare cellular responses to Dex treatment and their recovery, we specifically 
focused on individual protein secretion by different cell strains; the secretion profiles for 
MYOC are shown in figure 1. As reported previously, we observed that MYOC was highly 
induced in all five HTM cell strains treated with Dex for one or four weeks (Stamer et al., 
1998). In the one week Dex treatment group, induction of MYOC ranged from 3.5-fold to 
26.3-fold in presence of Dex, depending upon the cell strain (figure 2A). Recovery was also 
variable, with some cell strains returning back to normal levels within a few days, whereas 
others took weeks. Interestingly, one cell strain (HTM133) responded by continuing to 
elevate MYOC levels even after treatment withdrawal, and then having reduced levels 
compared to control weeks later. While the magnitude increase in secretion varied (3.9-fold 
to 12.5-fold), the secretion pattern for MYOC was more consistent amongst the different cell 
strains after 4 weeks of Dex treatment (figure 2B). In all strains, recovery from Dex 
withdrawal took much longer, with MYOC secretion remaining elevated for two weeks; 
gradually decreasing to normal levels. HTM133 was unique in that during recovery MYOC 
descended below starting levels two weeks after withdrawal. Combined data from all five 
cell strains is shown in figure 2C. On average, we observed about a 17-fold increase in 
Li et al. Page 5





















MYOC secretion in both the one week and four weeks Dex treatment groups. The one week 
treatment group recovered to baseline levels at mean of 7 days after withdrawal, while the 
four week treatment group took over two weeks to recover on average.
3.2 Matrix Metalloproteinase-2
Next we analyzed MMP2 secretion patterns by the same 5 HTM strains (figure 3). 
Densitometry of MMP2-specific bands on Western blots that correspond to cells treated with 
Dex (or after withdrawal) were normalized to untreated control at each time point. Shown in 
figure 3A are normalized data showing individual responses of five HTM cell strains treated 
for 1 week with Dex and were monitored for 7 weeks after removal of Dex. Figure 3B shows 
normalized data from cells treated with Dex for 4 weeks and were observed for an additional 
4 weeks without Dex. Secretion of MMP2 was significantly lower after 1 week of Dex 
treatment; however individual cell strain responses ranged from 28% to 48%. MMP2 levels 
returned to normal in all cell strains 11 days after Dex removal. Similarly, data in figure 3B 
show that individual cell strains responded differently to 4 weeks of Dex treatment, with 
MMP2 secretion reduced by 28% to 58%. Interestingly, recovery profiles from Dex removal 
was also quite different between cell strains, with some strains returning MMP2 secretion 
level to normal within 9 days and others (HTM123 and HTM133) actually increasing 
MMP2 secretion weeks later. Combined data from all five cell strains are shown in figure 
3C. Average decrease in MMP2 secretion after 1 week and 4 weeks treatment was about the 
same at 41% and 40%, respectively. The mean recovery time back to normal levels took 
about 7 days for the 1 week treated group and 4 days in 4 week treatment group, apparently 
due to disparity in recovery between individual cell strains.
Effects of dex on MMP2 activity were also examined at select treatment and recovery time 
points as shown in figure 4. Both active- (68 kDa) and pro-forms (72 kDa) of MMP2 are 
visible on gels. However, the majority of MMP2 in HTM cell culture supernatant appears its 
pro-form (72 kDa), which is consistent to previous reports (Li et al., 2011). Summarized 
data from both forms of MMP2 show that MMP2 activity was significantly reduced but at 
lower levels at 1 week and 4 weeks treatment compared to protein measured by western blot 
(26% and 23% respectively). MMP2 activity returned to baseline levels after 3 weeks of 
recovery from either 1 week or 4 weeks of dex treatment.
3.3 Fibronectin
The last secreted protein that we examined was FN. Shown in figure 5A are results from 
experiments testing effects of Dex treatment for 1 week and recovery over 7 weeks. 
Interestingly, we found that FN secretion was elevated in 4 strains of HTM cells, but was 
decreased in 1 cell strain (HTM122). The increase in FN was relatively small for four cell 
strains compared to MYOC (range: 1.14–1.46-fold). Conversely, the secretion of FN 
decreased by 26% in HTM122. Recovery was rather slow in all but HTM122, taking nearly 
two weeks to reach starting levels. The induction of FN by four cell strains was variable, but 
more robust (1.4–2.5-fold) after 4 weeks of Dex treatment (figure 5B). Similar to before, FN 
secretion from HTM122 was reduced as a result of prolonged Dex treatment. The decrease 
in FN secretion stayed down for one additional week after Dex withdrawal. Figure 5C shows 
combined data of FN secretion in the presence and absence of Dex treatment from all 5 cell 
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strains. Despite the fact that HTM122 cell secretion of FN was more than two standard 
deviations outside of range established by other four cell strains, the summary from all five 
stains still showed clear increase of FN at both 1 week and 4 weeks of Dex treatment. Mean 
increase in FN secretion was 1.24-fold after one week of Dex treatment (average of day 11 
to day 21) and 1.52-fold after four weeks of treatment (average of day 11 to day 52 or day 
28 to day 52). Recovery was slow in both groups, with the one week treatment group taking 
two weeks to return to baseline and the four week group on average taking almost four 
weeks.
3.4 Correlation between Secretion of FN and MYOC by Cells Treated with Dex
The level of FN secretion after Dex treatment appeared to negatively correlate changes in 
secretion of MYOC when comparing individual cell strains (compare figures 2A/B with 
5A/B). In order to assess the degree of correlation between secretion of FN and MYOC, 
Spearman and Kendaul Tau rank correlation tests were conducted with magnitude of 
response in secretion of FN to the change of MYOC induction based on Western blot data of 
FN and MYOC from 4 weeks Dex treatment and recovery of all five HTM cell strains. 
Analysis of the correlation between FN and MYOC from all time points in 4 weeks 
treatment plus recovery groups was as follows: Spearman correlation coefficient = −0.15 (P 
= 0.14) and Kendall Tau correlation coefficient = −0.10 (P = 0.15), which were suggestive of 
relationship but not significantly. Analysis of only the 4 weeks Dex treatment times, 
averaging magnitude of effect for each cell strain the results were as follows: Spearman 
correlation coefficient improved = −0.7 (P = 0.19) and Kendall Tau correlation coefficient = 
−0.6 (P =0.14) (Table 1). Lastly, examination of the 4 week recovery period, comparing 
mean effect of each cell strain, produced the following results: Spearman correlation 
coefficient = − 0.9 (P = 0.04) and Kendall Tau correlation coefficient = −0.8 (P = 0.05), 
indicating a significant negative correlation between FN and MYOC using both correlation 
analysis methods (table 1). In contrast, we observed no correlation between the age of 
donors from which HTM cell strains were obtained and response to Dex (table 1).
4. Discussion
In this study, we document the secretion response and recovery profile of five different HTM 
cell strains exposed to short and long-term Dex. We monitored three proteins involved in 
ECM formation and remodeling, MMP2, MYOC and FN, over an eight weeks examination 
period. Our major finding was that responses to treatment and recovery was highly variable, 
depending upon the cell strain. In 14 out of 15 cases, cells responded to treatment in the 
same direction; however, the magnitude of response, duration and recovery times were 
unpredictable. Interestingly, we observed that MYOC and FN secretion levels were inversely 
related when comparing responses and recovery from different cell strains. To our 
knowledge, this is the most comprehensive study of differential response profiles of 5 
different cell strains following Dex treatment and withdrawal that models treatment times in 
vivo.
The treatment regimen and drug concentrations were selected based on patient responses in 
the clinic and in vivo models. Data show GC-induced ocular hypertension onset is 1–4 
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weeks after treatment, with IOP returning to normal between 1–3 weeks after treatment 
stoppage. (Armaly, 1963; Clark et al., 1995; Overby et al., 2014). The 100 nM Dex 
concentration was chosen for treatments based on previous data showing measureable 
responses to long term treatment in outflow cells without inducing cytotoxicity (Jain et al., 
2013; Sharma et al., 2013; Shepard et al., 2001; Stamer et al., 2013; Steely et al., 1992; 
Underwood et al., 1999; Yun et al., 1989) and aqueous humor concentration after topical 
application in the range of 50–1000 nM (Awan et al., 2009).
MMP2, MYOC, and FN were selected for study because they are constitutively secreted, 
and thus easily monitored over time in culture. Moreover, all three have been shown to be 
responsive to Dex treatment in multiple studies and are thought to be critical proteins 
involved ECM homeostasis in the trabecular meshwork (Acott and Kelley, 2008; Chuang et 
al., 2015; Nguyen et al., 1998; Polansky et al., 2000; Stamer et al., 2013; Steely et al., 1992; 
Wordinger et al., 2007). Although, we could not account for their proportional incorporation 
into the TM cell monolayer ECM, we were able to monitor their steady-state levels in 
conditioned media. MMP2 is involved in the proteolysis of type IV collagen, usually 
associated with basement membranes (De Groef et al., 2013). Reduction of MMP2 by Dex 
(Chuang et al., 2015; Stamer et al., 2013), as we observed in all five cell strains in the 
present study, may contribute to increased basement membrane accumulation below the SC 
inner wall. Previous studies found that GC treatment resulted in a doubling of SC inner wall 
covered by basement membrane in both living mice and humans (Johnson et al., 1997; 
Overby et al., 2014; Tektas et al., 2010).
MYOC was first discovered as a protein that is uniquely induced upon glucocorticoid 
treatment of TM cells (Nguyen et al., 1998; Polansky et al., 1997; Stone et al., 1997). In fact, 
the increased expression of MYOC caused by Dex is currently used to characterize cultured 
TM cells (Lin et al., 2007; Mao et al., 2012; Stamer et al., 1998). In the present study and 
others, the profile of MYOC up-regulation by DEX was dose- and time-dependent, very 
similar to the course of development of steroid-induced glaucoma (Nguyen et al., 1998) 
(Shepard et al., 2001; Tamm et al., 1999); suggesting that MYOC plays a role in GC-induced 
glaucoma (Shepard et al., 2001). While it was found that MYOC was dramatically induced 
in all five HTM cell strains, differences between cell strains were noticeable in their 
recovery profiles. For example, we observed that MYOC expression was elevated for much 
longer after Dex withdrawal in HTM120 (11 month-old) and 122 (54 year-old) than other 
cell strains. Similarly, others have observed previously that a higher concentration of Dex 
(500 nM) treatment for 6 days resulted in a two week recovery period for MYOC (Faralli et 
al., 2015). The significance of this delay in terms of GC-induced glaucoma is uncertain and 
needs to be explored further. Clearly, induction of myocilin by GCs alone does not impede 
outflow and cause GC-induced glaucoma (Gould et al., 2004). It is likely that MYOC 
participates in a pathway that impacts outflow function, which is evident when mutated, 
causing ocular hypertension and glaucoma (Stone et al., 1997).
In contrast, a clear association between enhanced deposition of the ECM glycoprotein FN 
with POAG and GC-induced glaucoma has been documented (Babizhayev and Brodskaya, 
1989; Rodrigues et al., 1980; Steely et al., 1992). Increases in FN expression have been 
found in glaucomatous TM tissues and aqueous humor of patients (Acott and Kelley, 2008; 
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Wordinger et al., 2007). FN is a multifunctional and ubiquitous ECM glycoprotein that is 
one of the major ECM proteins in the TM (Hann et al., 2001). FN plays a number of 
important roles in the ECM of outflow tissues, likely providing mechanical support for cell 
attachment and regulating many of the biological processes including matrix production, 
ECM turnover, gene expression, growth factor signaling, and cytoskeletal organization 
(Calderwood, 2004; Ivaska and Heino, 2000; Lee and Juliano, 2004; Morgan et al., 2007; 
Schwartz and Assoian, 2001). FN and its receptors also are one of the modulators of cellular 
response to physical forces such as tissue stretching (Katsumi et al., 2005), which may 
underlie a role for FN in outflow resistance changes in response to changes in IOP (Faralli et 
al., 2009). In our study, we found that FN secretion increased by ~47 % in two cell strains 
and ~2-fold in two other cell strains. Unexpectedly, we observed that FN secretion by one 
cell strain (HTM122) actually decreased in response to both one and four week Dex 
treatments, which to our knowledge has not been previously reported. Our results can be 
compared to that of Clark’s group who observed a ~2-fold elevation of FN in glaucomatous 
TM cells exposed to Dex (100 nM), ~50–60% increase in two normal TM cell strains and no 
increase in one normal strain (Steely et al., 1992). Taken together, our results and that of 
Clark emphasize the importance of using more than one primary TM cell strain for studies.
We found that there is an apparent inverse relationship between recovery of MYOC and FN 
in the five HTM cell lines. For example, after 4 weeks Dex treatment, MYOC levels in 
HTM133 returned to normal within 2 weeks, however, FN stayed up 4 more weeks. In 
another instance, the dramatic upregulation of MYOC in HTM122 corresponded to the 
reduction of FN. By comparison, a relatively lower induction of MYOC by Dex in HTM123 
was correlated to the consistent higher levels of FN (table 1). In HTM120 and 124, the small 
increase of FN corresponded to higher induction of MYOC by Dex. When comparing all 
data points (four weeks of treatment and response) or mean change due to treatment for each 
cell strain, correlation analysis of MYOC and FN showed a trending inverse relationship that 
did not reach statistical significance. However, when comparing just the recovery phase after 
four weeks of Dex, we found a significant negative correlation between FN and MYOC 
secretion (table 1). This apparent relationship needs to be explored further.
In summary, this in vitro study examined the effects of two different Dex treatment 
regimens, mimicking the 1 and 4 week topical treatment times practiced in vivo. Using 5 
different TM cell strains, we monitored the secretion of three proteins that are important 
regulators of ECM homeostasis in the TM, during and 4–7 weeks after stoppage of Dex 
treatment. We observed that each cell strain produced a unique response and recovery 
profile, emphasizing the need to develop personalized treatments for those with ocular 
hypertension in GC-induced and other types of glaucoma.
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• Secretory responses to dexamethasone and recovery after cessation of 
treatment was highly variable, depending upon the human TM cell strain 
tested.
• In 14 out of 15 cases, human TM cell strains responded to dexamethasone 
treatment in the same direction, however the magnitude of response, duration 
and recovery times were unpredictable.
• MYOC and FN secretion levels were inversely related when comparing 
dexamethasone responses and recovery from different human TM cell strains.
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Figure 1. Dexamethasone (Dex)-induced changes in the secretion of MYOC, MMP2 and FN from 
five different HTM cell strains
Five HTM cell strains were cultured in 1% DMEM medium for at least one week and then 
treated with Dex (100 nM, three times/week) for 1 or 4 weeks. In the 1 week treatment 
group, the secretion profile after cessation of Dex treatment was monitored for an additional 
7 weeks, while the 4 week treatment group was monitored for an additional 4 weeks after 
Dex withdrawal. Protein levels of MYOC, MMP2 and FN in cell culture supernatant was 
monitored by Western blot: MYOC (size: 55/57kDa), MMP2 (size: 72kDa), and FN (size: 
263kDa). Secretion levels by all five HTM cell strains (HTM124, 123, 120, 133 and 122) are 
displayed.
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Figure 2. Quantitative analysis of MYOC protein secretion by five HTM cell strains over time 
during and after Dexamethasone (Dex) treatment
Densitometry was performed on Western blot bands (55/57 doublet) that correspond to 
MYOC using ImageJ software. Panel A shows results from cells treated with Dex for 1 week 
and were followed for 7 weeks after withdrawal; Panel B shows protein profile of cells 
treated with Dex for 4 weeks and were followed for an additional 4 weeks after cessation of 
treatment. Panel C shows combined data (mean ± SE) from all five cell strains in each 
treatment group over the 8 week evaluation period. *, P < 0.5 by Mann-Whitney U Test.
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Figure 3. Quantitative analysis of MMP2 protein levels in conditioned media from five HTM cell 
strains
Western blots were immunostained with mouse monoclonal antibody against MMP2 and the 
bands intensities were analyzed by densitometry. Panel A shows results following 1 week of 
Dex treatment and 7 weeks of withdrawal. Panel B show data obtained after 4 weeks of Dex 
treatment and 4 weeks of withdrawal. Summarized data from all five cell strains show mean 
expression (± SE) levels at each time point are shown in panel C. *, P < 0.5 by Mann-
Whitney U Test.
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Figure 4. Reduction of MMP2 activity in HTM cell supernatant by dexamethasone treatment
Zymography was performed to assess gelatinase activity in media conditioned by HTM cells 
treated with dexamethasone (1 week and 4 weeks), and followed up 3 weeks recovery for 
both treatment time points. Panel A shows a representative zymogram with prominent 
MMP2 bands of digestion in the presence/absence of Dex for 1 week or 4 weeks, plus 
following 3 weeks Dex withdrawal. Panel B displays quantitative densitometry of MMP2 
activity results from all five cell strains. *, p < 0.05 compared to vehicle treated group at 
each time point. Labels: Dex1w or dex4w: Dex treatment for 1 week or 4 weeks; 
dex1w_R3w or dex4w_R3w: after 1 week or 3 weeks Dex treatment, cells were incubated in 
fresh medium for additional 3 more weeks.
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Figure 5. Quantitative analysis of FN protein levels in conditioned supernatant from five HTM 
cell strains
Western blots were immunostained with mouse monoclonal antibody against FN and the 
band intensities from each time point in each cell strain was analyzed. Panel A shows results 
following 1 week of Dex treatment and 7 weeks of withdrawal. Panel B displays findings of 
4 weeks of Dex treatment and 4 weeks of withdrawal. Summarized expression levels (mean 
± SE) of all five cell lines are shown in panel C. *, P < 0.5 by Mann-Whitney U Test.
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